Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Crescent Biopharma	$13.80 +1.5%	$13.87	$10.83 ▼ $63.00	$269.79M	1.51	44,694 shs	61,667 shs
GERN Geron	$1.39 -2.8%	$1.37	$1.09 ▼ $4.83	$886.85M	0.73	12.69 million shs	4.36 million shs
RIGL Rigel Pharmaceuticals	$41.36 +6.2%	$22.87	$12.00 ▼ $41.86	$741.87M	1.21	290,168 shs	1.08 million shs
ZBIO Zenas BioPharma	$16.32 +3.0%	$12.92	$5.83 ▼ $26.25	$687.24M	N/A	180,866 shs	431,240 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Crescent Biopharma	-1.38%	+4.78%	+1.95%	-98.23%	-98.23%
GERN Geron	-0.69%	+5.93%	+15.32%	+6.72%	-67.94%
RIGL Rigel Pharmaceuticals	-2.82%	+12.80%	+107.13%	+85.96%	+206.37%
ZBIO Zenas BioPharma	-8.28%	-0.31%	+15.44%	+44.88%	+1,584,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBIO Crescent Biopharma	3.8152 of 5 stars	4.7	0.0	3.7	2.5	1.7	0.6
GERN Geron	3.1936 of 5 stars	3.3	1.0	1.3	2.6	1.7	0.6
RIGL Rigel Pharmaceuticals	1.6581 of 5 stars	1.2	1.0	0.0	2.4	1.7	3.1
ZBIO Zenas BioPharma	1.4828 of 5 stars	3.5	0.0	0.0	1.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBIO Crescent Biopharma	3.40	Buy	$25.50	85.72% Upside
GERN Geron	2.56	Moderate Buy	$4.19	200.18% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-6.91% Downside
ZBIO Zenas BioPharma	3.00	Buy	$36.67	130.03% Upside

Current Analyst Ratings Breakdown

Latest CBIO, GERN, RIGL, and ZBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
7/10/2025	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$1.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	$6.92 per share	N/A
GERN Geron	$76.99M	11.56	N/A	N/A	$0.41 per share	3.40
RIGL Rigel Pharmaceuticals	$267.92M	2.75	$1.10 per share	37.14	$4.57 per share	8.98
ZBIO Zenas BioPharma	$5M	134.25	N/A	N/A	$5.69 per share	2.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBIO Crescent Biopharma	-$37.88M	-$34.93	N/A	N/A	N/A	N/A	-106.06%	-86.60%	N/A
GERN Geron	-$174.57M	-$0.13	N/A	N/A	N/A	-53.52%	-31.37%	-16.01%	11/6/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.57	39.08	N/A	36.51%	438.89%	57.03%	11/6/2025 (Estimated)
ZBIO Zenas BioPharma	-$156.99M	-$3.55	N/A	∞	N/A	N/A	-59.21%	-50.56%	8/21/2025 (Estimated)

Latest CBIO, GERN, RIGL, and ZBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	N/A	N/A	N/A	$1.25 million	N/A
8/12/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	-$1.25	-$0.23	-$1.25	$5.00 million	N/A
8/6/2025	Q2 2025	GERN Geron	-$0.03	-$0.02	+$0.01	-$0.02	$47.30 million	$49.04 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBIO Crescent Biopharma	N/A	9.21	9.21
GERN Geron	0.46	7.87	6.79
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
ZBIO Zenas BioPharma	N/A	5.23	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBIO Crescent Biopharma	75.19%
GERN Geron	73.71%
RIGL Rigel Pharmaceuticals	66.23%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
CBIO Crescent Biopharma	8.70%
GERN Geron	7.42%
RIGL Rigel Pharmaceuticals	9.04%
ZBIO Zenas BioPharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBIO Crescent Biopharma	50	19.55 million	17.85 million	No Data
GERN Geron	229	638.02 million	590.68 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.32 million	Optionable
ZBIO Zenas BioPharma	N/A	42.11 million	35.16 million	N/A

CBIO, GERN, ZBIO, and RIGL Headlines

Recent News About These Companies

Zenas BioPharma (NASDAQ:ZBIO) Trading 8.1% Higher - Should You Buy?

2 hours ago | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Zenas BioPharma

August 17 at 8:27 AM | marketbeat.com

What is Wedbush's Estimate for Zenas BioPharma Q3 Earnings?

August 17 at 8:27 AM | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to Sell at Wall Street Zen

August 17 at 2:50 AM | marketbeat.com

Wedbush Has Pessimistic View of Zenas BioPharma Q3 Earnings

August 17 at 2:04 AM | americanbankingnews.com

Zenas BioPharma Q3 EPS Forecast Decreased by HC Wainwright

August 16, 2025 | americanbankingnews.com

Zenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on Thursday

August 15, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

August 14, 2025 | marketbeat.com

Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit

August 13, 2025 | msn.com

Zenas BioPharma Reports Q2 2025 Financial Results

August 13, 2025 | tipranks.com

Zenas BioPharma expects cash to fund operations into Q4 of 2026

August 12, 2025 | msn.com

Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year

August 12, 2025 | msn.com

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 12, 2025 | globenewswire.com

44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.

August 9, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?

August 6, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?

August 5, 2025 | marketbeat.com

3 Highly Shorted Stocks That Could Be the Next Wall Street Sensations

August 2, 2025 | msn.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's Why

July 29, 2025 | marketbeat.com

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

July 28, 2025 | seekingalpha.com

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.5% - Time to Sell?

July 26, 2025 | marketbeat.com

Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma

July 3, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, GERN, ZBIO, and RIGL Company Descriptions

Crescent Biopharma NASDAQ:CBIO

$13.80 +0.20 (+1.47%)

As of 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Geron NASDAQ:GERN

$1.39 -0.04 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$1.41 +0.02 (+1.65%)

As of 04:23 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$41.36 +2.42 (+6.21%)

Closing price 04:00 PM Eastern

Extended Trading

$41.40 +0.05 (+0.11%)

As of 04:20 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Zenas BioPharma NASDAQ:ZBIO

$16.32 +0.47 (+2.97%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time